Loading
A phase 2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT06668961 by Sichuan Baili Pharmaceutical Co., Ltd., with 48 participants enrolled, started 2024-11-07 and due to reach its primary completion in 2026-11. Interventions recorded: SI-B001, SI-B003. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares SI-B001, SystImmune / Sichuan Biokin.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, SystImmune / Sichuan Biokin, Head and neck squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/